Explore more Johnson & Johnson sites:
Share
Our Work to Make HIV History
The HIV epidemic continues to be a significant global health challenge with more than 38 million people living with HIV. Around the world, advocates, researchers and other inspiring individuals are working on the frontlines to better the lives of people living with and impacted by HIV.
Collaborating to Improve Lives
We advance the science and have helped to introduce nine medicines for HIV to empower people to live with HIV as a chronic condition rather than the terminal illness it once was.
-
To show how far we've come, Johnson & Johnson's Brian Woodfall, M.D. returns to the clinic in Canada where he treated people living with HIV in the 1990's and discusses how we've evolved treatment since then.
-
To mark the AIDS 2022 conference in Montreal, Johnson & Johnson is honored to join with Equal Pride to recognize 10 “HIV Heroes” for their leadership in the quest to #MakeHIVHistory.
-
In the HIV community, taking care of ourselves and each other has never been more important. When we share our stories, we are stronger. We are courageous. We are fearless. Find a wealth of information, including self-care tips, ambassador video stories sharing personal insight and inspiration and more.
Champions of Science
We’re proud to have played a role in bringing forward nine medicines for people living with HIV, redefining what it means to live with this virus and advancing our mission to make HIV history.
Our vision is a world without HIV. That’s why we are committed to advancing the innovation needed to help stop the global HIV epidemic in its tracks.
Our commitment is unwavering, and we remain dedicated to ushering in new advancements in prevention and therapy for the HIV community. Together, we’re helping to build a world without HIV and we won't stop until we make HIV history.
For decades, the Johnson & Johnson Foundation has partnered with local organizations to equip health workers with specialized training, education and novel technologies to support people living with HIV and help prevent future infections.
Addressing the Needs of the World’s Most Vulnerable Populations
Our Global Public Health team is working with partners like PEPFAR, EGPAF, Global Fund and others in those countries hardest hit by HIV.
Stories: People and Progress
Nurses on the Front Lines
-
June 07, 2019How one nurse revolutionized patient care during the AIDS crisis.Back to top
Inspiring nurse leaders of tomorrow with lessons from the nurses of Ward 5BHow We’re Working to Make HIV History
Dr. Paul Janssen Begins Screening Anti-HIV Compounds
The late Dr. Paul Janssen and the Janssen Research Foundation begin a new partnership with the Rega Institute to screen anti-HIV compounds.
Clinical Development Begins
The Janssen Research Foundation moves its first compound for the treatment of HIV into clinical development.
Janssen Partners With Tibotec
The Janssen Research Foundation signs a five-year agreement with Tibotec and founder Dr. Rudi Pauwels to continue the quest for better HIV inhibitors. A year later, Dr. Paul Stoffels co-founds Virco with Dr. Pauwels.
Johnson & Johnson Acquires Tibotec-Virco NV, Belgian Pharmaceutical R&D Company
The company becomes part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and begins late-stage trials on a breakthrough medicine.
Janssen’s First HIV Medicine Receives U.S. FDA Accelerated Approval
Janssen’s next-generation protease inhibitor is granted accelerated approval by the U.S. Food and Drug Administration (FDA) prior to finishing Phase III trials.
Janssen’s Second HIV Medicine Granted Accelerated Approval by U.S. FDA
Janssen’s next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) is approved for use in combination with other antiretroviral medicines for patients with established resistance to other drugs.
Johnson & Johnson Introduces Third HIV Medication
Janssen’s third HIV medication, a next-generation NNRTI, is approved by the U.S. FDA. The company partners with Gilead and then ViiV Healthcare to create a single-tablet, multi-drug HIV regimen based on this NNRTI.
First-of-Its-Kind Drug Donation Program for Pediatric HIV Launched
Janssen announces it will donate two of its HIV medicines, including child-friendly formulations, free of charge to eligible countries in sub-Saharan Africa.
Johnson & Johnson Launches New Horizons Collaborative
Johnson & Johnson and its partners launch the New Horizons Collaborative in sub-Saharan Africa to improve access and scale-up of pediatric HIV treatment. The program is later expanded to 11 total countries.
Janssen Announces Collaboration With Gilead to Develop Single-Tablet Regimen
Janssen and Gilead collaborate in the clinical development of a once daily, single-tablet regimen containing Janssen’s protease inhibitor for the treatment of people living with HIV.
Imbokodo Trial Launches in Southern Africa
The Phase 2b efficacy trial of Janssen’s investigational preventive HIV vaccine regimen begins in Africa.
The study did not continue after the results of the primary analysis were announced in August 2021.
First Single-Tablet, Complete Two-Drug Regimen Approved by U.S. FDA
A new treatment comprised of medicines developed by ViiV Healthcare and Janssen is approved as a once-daily regimen, offering a new and simplified option for people living with HIV.
Johnson & Johnson Launches Youth-Led DREAMS Thina Abantu Abasha Program
Johnson & Johnson, joined by the United Nations Population Fund, launch the initiative to promote empowerment and HIV prevention education among adolescent girls and young women in sub-Saharan Africa.
Global Partners Pledge Over $1.2 Billion to Launch the MenStar Coalition
Johnson & Johnson joins Sir Elton John; Prince Harry, Duke of Sussex; and other global partners to support the launch of the MenStar Coalition to expand diagnosis and treatment of HIV in men.
U.S. FDA Approves First Single Tablet Regimen Containing a Protease Inhibitor for the Treatment of HIV
Johnson & Johnson’s once-daily single-tablet regimen is approved by the U.S. FDA, offering a new treatment option for adults living with HIV.
Johnson & Johnson Commits $500 Million to Help End HIV and Tuberculosis
Johnson & Johnson announces four-year commitment, focused on developing new innovations and accelerating the delivery of existing and new tools to combat both epidemics.
Mosaico Vaccine Trial Enrolls First Participant
The Phase 3 trial launches to test the efficacy of Janssen’s investigational preventive HIV vaccine regimen in the Americas and Europe. The study was discontinued in January 2023.
WHO Recommends IPM’s Vaginal Ring for the Prevention of HIV
The world’s first long-acting, discreet HIV prevention option for women, developed by the International Partnership for Microbicides under an exclusive license from Janssen, is recommended for use by the WHO.
European Commission Authorizes the First Long-Acting Injectable Regimen
The European Commission authorizes the world’s first long-acting injectable treatment regimen for HIV, which was co-developed by Johnson & Johnson and ViiV Healthcare.
Janssen Announces Positive Long-Term Data for Every Two Months Long-Acting Injectable Regimen
Positive 96-week data presented by Janssen on the long-acting, injectable treatment regimen demonstrates the efficacy the regimen over a six-times-per-year dosing schedule.
U.S. FDA Expands Label of Long-Acting HIV Treatment
U.S. FDA approves every-two-months dosing schedule for long-acting injectable HIV treatment regimen co-developed by Johnson & Johnson & ViiV Healthcare
U.S. FDA Approves Streamlined Treatment Initiation Process
U.S. FDA gives adults with HIV the option to begin taking Johnson & Johnson and ViiV Healthcare’s long-acting injectable HIV treatment regimen without oral lead-in period
IPM’s Dapivirine Ring Approved by SAHPRA
South African Health Products and Regulatory Authority (SAHPRA) approves once-monthly dapivirine vaginal ring, developed by International Partnership for Microbicides under license from Janssen.
Long-Acting Treatment Regimen Approved for Adolescents
U.S. FDA approves first long-acting injectable HIV treatment regimen, co-developed by Johnson & Johnson and ViiV Healthcare, for eligible adolescents.
June 1985
October 1990
June 1994
April 2002
June 2006
January 2008
May 2011
December 2013
September 2014
December 2014
November 2017
November 2017
May 2018
July 2018
July 2018
October 2019
November 2019
December 2020
December 2020
March 2021
February 2022
March 2022
March 2022
April 2022
Our Latest HIV News
-
InnovationNovember 30, 2021
-
InnovationJuly 26, 2021